Find out how immunotherapy can improve cancer treatment outcomes and the systemic barriers limiting its widespread use.

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

Comprehensive review synthesizes clinical learnings from BEXMAB and MATINS trials, detailing the potential of bexmarilimab in overcoming immune resistance in cancer TURKU, FI / ACCESS Newswire / ...

Rare tumors, although individually uncommon, collectively account for a considerable proportion of cancer diagnoses and pose unique clinical and biological ...

Please provide your email address to receive an email when new articles are posted on . 0.13% of subcutaneous immunotherapy injections led to systemic reactions. 15.8% of systemic reactions in SCIT ...

Findings showed Orca-T statistically significantly improved survival free of moderate to severe cGvHD vs alloHSCT at 1 year. The Food and Drug Administration (FDA) has accepted for Priority Review the ...

Generally, the standard treatment for solid tumors is surgery. However, a recent study from New York City-based Memorial Sloan Kettering Cancer Center found immunotherapy can effectively treat these ...

A Prescription Drug User Fee Act target date of October 30, 2026 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...

Emerging immunotherapies in multiple myeloma mainly consist of immunomodulatory imid drugs, monoclonal antibodies, immune checkpoint inhibitors, antibody–drug conjugates, chimeric antigen receptor T ...

In August 2015, former President Jimmy Carter thought he had mere weeks to live. His skin cancer ‒ metastatic melanoma ‒ had seeded malignant tumors in his liver and brain. Conventional radiation ...